Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
The global Infliximab and biosimilar market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Infliximab and biosimilar volume and value at global level, regional level and company level. From a global perspective, this report represents overall Infliximab and biosimilar market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Infliximab and biosimilar in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Infliximab and biosimilar manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Janssen Biotech
Merck and Co.
Pfizer
...
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Infliximab
infliximab-dyyb
infliximab-abda
Segment by Application
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis
Summary:
Get latest Market Research Reports on Infliximab and biosimilar. Industry analysis & Market Report on Infliximab and biosimilar is a syndicated market report, published as Global Infliximab and biosimilar Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Infliximab and biosimilar market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.